Nuclear Medicine Market

Nuclear Medicine Market (Type: Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine; Application: Cardiology, Neurology, Oncology, Pulmonology, Gastroenterology and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Nuclear Medicine Market Outlook 2031

  • The global industry was valued at US$ 5.2 Bn in 2022
  • It is projected to advance at a CAGR of 9.2% from 2023 to 2031 to reach more than US$ 11.4 Bn by the end of 2031

Analysts’ Viewpoint

Rise in awareness and acceptance of nuclear medicine procedures are the key drivers of the global nuclear medicine market. Nuclear medicine provides accurate and early diagnosis of various medical conditions. Increase in adoption of advanced imaging technologies such as PET-CT and SPECT is expected to propel the global nuclear medicine industry growth during the forecast period. Furthermore, surge in usage of nuclear medicine procedures in the treatment of various medical conditions, such as cancer and cardiovascular diseases, is likely to bolster global nuclear medicine market size.

Increase in investment in research & development of new nuclear medicine procedures offers lucrative opportunities to market players. Companies are focusing on developing more efficient and cost-effective nuclear medicine procedures in order to increase market share.

Nuclear Medicine Market

Global Nuclear Medicine Market Introduction

Nuclear medicine refers to a specialized radiology field that utilizes small amounts of radioactive materials, known as radiopharmaceuticals, to examine the structure and function of organs. This imaging technique is an amalgamation of various disciplines such as chemistry, physics, mathematics, computer technology, and medicine. It is particularly useful in the early detection and treatment of diseases, such as thyroid cancer.

By analyzing the behavior of radionuclides in the body during a nuclear scan, healthcare professionals can diagnose a range of conditions, including infections, tumors, cysts, hematomas, and organ enlargement. Additionally, nuclear scans are helpful in assessing organ function and blood circulation.

Positron emission tomography (PET) is a type of nuclear medicine that uses a tracer to demonstrate the natural activity of cells, providing detailed information on organ functionality and cell damage. PET scans are often combined with three-dimensional imaging techniques, such as computed tomography (CT) or magnetic resonance imaging (MRI), to produce a more comprehensive picture of the organ.

Increase in Incidence of Cancer and Cardiovascular Diseases

Surge in incidence of cancer and cardiovascular diseases is one of the major drivers of the global nuclear medicine market growth. Nuclear medicine plays a critical role in the diagnosis, staging, and treatment of these diseases.

Cancer is a leading cause of death globally, and the number of new cases is expected to increase in the next few years. Nuclear medicine techniques, such as PET and SPECT, are widely used for cancer diagnosis, staging, and treatment planning. Radiopharmaceuticals are used to target cancer cells and deliver radiation therapy directly to the tumor site, reducing the risk of damage to healthy tissue.

Cardiovascular diseases, including heart disease and stroke, are also major global health concerns. Nuclear medicine techniques such as myocardial perfusion imaging (MPI) and positron emission tomography (PET) are commonly used for the diagnosis and management of cardiovascular diseases.

Aging population and increase in demand for personalized medicine are also driving the global nuclear medicine industry. Rise in the geriatric population increases the incidence of chronic diseases that require nuclear medicine interventions. Personalized medicine, which involves tailoring treatment to an individual's specific genetic and biological characteristics, relies primarily on nuclear medicine techniques for accurate diagnosis and treatment.

Overall, increase in incidence of cancer & cardiovascular diseases, aging population, and rise in demand for personalized medicine are expected to drive nuclear medicine market demand in the next few years.

Rise in Awareness and Acceptance of Nuclear Medicine Procedures

Rise in awareness and acceptance of nuclear medicine procedures are the key drivers of global nuclear medicine market development. Demand for nuclear medicine procedures is expected to increase significantly, as more people become aware of the benefits of the procedures.

One of the key advantages of nuclear medicine procedures is the ability to provide accurate and early diagnosis of various medical conditions. Nuclear medicine procedures are non-invasive and use small amounts of radioactive materials to produce detailed images of the body's internal organs and tissues. These images can help healthcare professionals detect and diagnose diseases at an early stage, which can significantly improve patient outcomes.

Nuclear medicine procedures are increasingly being used in the treatment of various medical conditions, such as cancer and cardiovascular diseases. Nuclear medicine therapies use radioactive materials to target and destroy cancer cells or other abnormal cells in the body, without causing significant damage to healthy cells.

Increase in acceptance of nuclear medicine procedures as a standard part of healthcare is another key driver of the market. As healthcare professionals become more familiar with nuclear medicine procedures and their benefits, they are more likely to recommend them to patients.

High-quality Images of Internal Body Parts Propelling Diagnostic Nuclear Medicine Segment

In terms of type, the diagnostic nuclear medicine segment accounted for the largest global nuclear medicine market share in 2022. Diagnostic nuclear medicine involves usage of radiopharmaceuticals to diagnose various medical conditions, including cancer, heart disease, and neurological disorders. It is a non-invasive imaging technique that provides high-quality images of the body's internal organs, tissues, and bones.

The diagnostic nuclear medicine segment is driven by increase in demand for accurate and effective diagnostic procedures. Rise in prevalence of chronic diseases, such as cancer and cardiovascular diseases, and surge in demand for early disease detection and prevention are fueling the growth of the segment.

The diagnostic nuclear medicine segment is benefiting from the increasing adoption of advanced imaging technologies such as PET-CT and SPECT. These imaging technologies provide high-resolution images that aid in accurate diagnosis and treatment planning.

Rise in Usage of Nuclear Medicine to Locate Cancerous Cells

Based on application, the oncology segment dominated the global nuclear medicine market in 2022. Nuclear medicine plays a critical role in the diagnosis and treatment of various types of cancers, including breast cancer, lung cancer, prostate cancer, and lymphoma. Nuclear medicine is used primarily for diagnosis, staging, and treatment of cancer.

Rise in prevalence of cancer across the world and increase in demand for effective cancer treatments are driving the oncology segment. Usage of PET-CT and SPECT imaging technologies is increasing in the diagnosis and treatment of cancer. These imaging technologies are used to locate cancerous cells and monitor the effectiveness of cancer treatments.

Availability of Infrastructure & Trained Personnel Fueling Hospitals Segment

In terms of end-user, the hospitals segment held the largest share of global nuclear medicine market value in 2022. Nuclear medicine is a medical specialty that uses radioactive substances to diagnose and treat various diseases. Hospitals are the primary end-users of nuclear medicine, where it is used for a range of diagnostic and therapeutic applications.

Hospitals have a significant demand for nuclear medicine products and services due to the large number of patients they serve. Nuclear medicine procedures are commonly used for the diagnosis and treatment of cancer, cardiovascular diseases, neurological disorders, and other medical conditions. Hospitals require a constant supply of radiopharmaceuticals, which are essential for nuclear medicine procedures.

Hospitals have the necessary infrastructure and trained personnel to perform complex nuclear medicine procedures. These have specialized departments that are dedicated to nuclear medicine, which are equipped with advanced imaging equipment such as PET-CT scanners and SPECT cameras.

Nuclear Medicine Market Regional Insights

Nuclear medicine is a global industry that is expected to experience significant growth in the next few years. North America is the largest market for nuclear medicine in 2022. This is ascribed to presence of advanced healthcare infrastructure, high healthcare spending, and large aging population.

Europe was the second largest market for nuclear medicine in 2022. The market in the region is driven by rise in prevalence of chronic diseases, increase in healthcare expenditure, and presence of a well-established pharmaceutical industry.

The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. This is ascribed to increase in demand for advanced medical imaging technologies, rise in healthcare expenditure, and surge in prevalence of chronic diseases. Countries such as China, Japan, and India are expected to be the major markets in the region.

The market in Middle East & Africa is likely to witness moderate growth during the forecast period. This is ascribed to increase in investment in healthcare infrastructure, rise in healthcare expenditure, and surge in prevalence of chronic diseases.

Analysis of Key Players

Expansion of product portfolio and merger & acquisition are the key strategies adopted by prominent manufacturers to increase market share and presence. GE Healthcare, Siemens Healthineers, Philips Healthcare, Cardinal Health, Bracco Imaging S.p.A., Curium Pharma, Eckert & Ziegler, Jubilant Radiopharma, Lantheus Medical Imaging, Nordion, Inc., Advanced Accelerator Applications (AAA), IBA Radiopharma Solutions, NorthStar Medical Radioisotopes, Polatom, and Isotopia Molecular Imaging are the prominent players in the global market.

Key Developments in Global Nuclear Medicine Market

  • In February 2023, Telix Pharmaceuticals Limited completed its joint research project with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced in February 2021. The goal of this project was to develop and validate a PSMA-targeting generator-based theranostic compound for urologic oncology using the beta-emitting isotope rhenium-188 (188Re).
  • In February 2023, United Imaging announced multiple partnerships in Middle East & Africa at Arab Health 2023. During this annual event, United Imaging and I-ONE Nuclear Medicine & Oncology Centre signed an MOU for a collaboration and research agreement for the first PET/MR uPMR 790 in the Gulf countries. The I-ONE Nuclear Medicine & Oncology Centre is the first of its kind in Saudi Arabia's western region.
  • In October 2021, the DRIVE-MRT (Molecular RadioTherapy) solution was developed in collaboration with Oncodesign, Covalab, CheMatech, and ABX-CRO. Designed to provide therapeutic development in nuclear medicine, this includes theranostics, which includes everything from therapeutic target validation, radiolabeled biological vector generation, lead optimization, preclinical candidate drug generation and IND, to clinical trial design and management.

The nuclear medicine market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Nuclear Medicine Market Snapshot

Attribute Detail
Size in 2022 US$ 5.2 Bn
Forecast (Value) in 2031 US$ 11.4 Bn
Growth Rate (CAGR) 9.2%
Forecast Period 2023-2031
Historical Data 2017-2021
Quantitative Units US$ Mn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s five forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Type
    • Diagnostic Nuclear Medicine
      • PECT Radiopharmaceuticals
      • PET Radiopharmaceuticals
    • Therapeutic Nuclear Medicine
      • Alpha Emitters
      • Beta Emitters
      • Brachytherapy Isotopes
  • Application
    • Cardiology
    • Neurology
    • Oncology
    • Pulmonology
    • Gastroenterology
    • Others
  • End-user
    • Hospitals
    • Diagnostic Centers
      • Individual Practice
      • Group Practice
    • Research Institutes
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries
Companies Profiled
  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Cardinal Health
  • Bracco Imaging S.p.A.
  • Curium Pharma
  • Eckert & Ziegler
  • Jubilant Radiopharma
  • Lantheus Medical Imaging
  • Nordion, Inc.
  • Advanced Accelerator Applications (AAA)
  • IBA Radiopharma Solutions
  • NorthStar Medical Radioisotopes
  • Polatom
  • Isotopia Molecular Imaging
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global nuclear medicine market in 2022?

It was valued at US$ 5.2 Bn in 2022

How big will the nuclear medicine industry be in 2031?

It is projected to reach more than US$ 11.4 Bn by 2031

What will be the CAGR of the nuclear medicine business during the forecast period?

It is anticipated to grow at a CAGR of 9.2% from 2023 to 2031

Which are the major factors driving demand for nuclear medicine?

Rise in prevalence of chronic diseases and development of new technologies such as PET/CT systems, SPECT/CT systems.

Which will be a lucrative region for nuclear medicine companies during the forecast period?

North America is projected to be an attractive market for companies.

Who are the prominent providers of nuclear medicine?

GE Healthcare, Siemens Healthineers, Philips Healthcare, Cardinal Health, Bracco Imaging S.p.A., Curium Pharma, Eckert & Ziegler, Jubilant Radiopharma, Lantheus Medical Imaging, Nordion, Inc., Advanced Accelerator Applications (AAA), IBA Radiopharma Solutions, NorthStar Medical Radioisotopes, Polatom, and Isotopia Molecular Imaging.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Nuclear Medicine Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Nuclear Medicine Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Technological Advancements

        5.2. List of FDA Approved Radioisotopes

        5.3. No. of Nuclear Medicine Centers in Major Countries

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Nuclear Medicine Market Analysis and Forecast, by Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Type, 2017-2031

            6.3.1. Diagnostic Nuclear Medicine

                6.3.1.1. PECT Radiopharmaceuticals

                6.3.1.2. PET Radiopharmaceuticals

            6.3.2. Therapeutic Nuclear Medicine

                6.3.2.1. Alpha Emitters

                6.3.2.2. Beta Emitters

                6.3.2.3. Brachytherapy Isotopes

        6.4. Market Attractiveness Analysis, by Type

    7. Global Nuclear Medicine Market Analysis and Forecast, by Application

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Application, 2017-2031

            7.3.1. Cardiology

            7.3.2. Neurology

            7.3.3. Oncology

            7.3.4. Pulmonology

            7.3.5. Gastroenterology

            7.3.6. Others

        7.4. Market Attractiveness Analysis, by Application

    8. Global Nuclear Medicine Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by End-user, 2017-2031

            8.3.1. Hospitals

            8.3.2. Diagnostic Centers

                8.3.2.1. Individual Practice

                8.3.2.2. Group Practice

            8.3.3. Research Institutes

        8.4. Market Attractiveness Analysis, by End-user

    9. Global Nuclear Medicine Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017-2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Nuclear Medicine Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Type, 2017-2031

            10.2.1. Diagnostic Nuclear Medicine

                10.2.1.1. PECT Radiopharmaceuticals

                10.2.1.2. PET Radiopharmaceuticals

            10.2.2. Therapeutic Nuclear Medicine

                10.2.2.1. Alpha Emitters

                10.2.2.2. Beta Emitters

                10.2.2.3. Brachytherapy Isotopes

        10.3. Market Value Forecast, by Application, 2017-2031

            10.3.1. Cardiology

            10.3.2. Neurology

            10.3.3. Oncology

            10.3.4. Pulmonology

            10.3.5. Gastroenterology

            10.3.6. Others

        10.4. Market Value Forecast, by End-user, 2017-2031

            10.4.1. Hospitals

            10.4.2. Diagnostic Centers

                10.4.2.1. Individual Practice

                10.4.2.2. Group Practice

            10.4.3. Research Institutes

        10.5. Market Value Forecast, by Country, 2017-2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Type

            10.6.2. By Application

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Nuclear Medicine Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Type, 2017-2031

            11.2.1. Diagnostic Nuclear Medicine

                11.2.1.1. PECT Radiopharmaceuticals

                11.2.1.2. PET Radiopharmaceuticals

            11.2.2. Therapeutic Nuclear Medicine

                11.2.2.1. Alpha Emitters

                11.2.2.2. Beta Emitters

                11.2.2.3. Brachytherapy Isotopes

        11.3. Market Value Forecast, by Application, 2017-2031

            11.3.1. Cardiology

            11.3.2. Neurology

            11.3.3. Oncology

            11.3.4. Pulmonology

            11.3.5. Gastroenterology

            11.3.6. Others

        11.4. Market Value Forecast, by End-user, 2017-2031

            11.4.1. Hospitals

            11.4.2. Diagnostic Centers

                11.4.2.1. Individual Practice

                11.4.2.2. Group Practice

            11.4.3. Research Institutes

        11.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Type

            11.6.2. By Application

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Nuclear Medicine Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Type, 2017-2031

            12.2.1. Diagnostic Nuclear Medicine

                12.2.1.1. PECT Radiopharmaceuticals

                12.2.1.2. PET Radiopharmaceuticals

            12.2.2. Therapeutic Nuclear Medicine

                12.2.2.1. Alpha Emitters

                12.2.2.2. Beta Emitters

                12.2.2.3. Brachytherapy Isotopes

        12.3. Market Value Forecast, by Application, 2017-2031

            12.3.1. Cardiology

            12.3.2. Neurology

            12.3.3. Oncology

            12.3.4. Pulmonology

            12.3.5. Gastroenterology

            12.3.6. Others

        12.4. Market Value Forecast, by End-user, 2017-2031

            12.4.1. Hospitals

            12.4.2. Diagnostic Centers

                12.4.2.1. Individual Practice

                12.4.2.2. Group Practice

            12.4.3. Research Institutes

        12.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Type

            12.6.2. By Application

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Nuclear Medicine Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Type, 2017-2031

            13.2.1. Diagnostic Nuclear Medicine

                13.2.1.1. PECT Radiopharmaceuticals

                13.2.1.2. PET Radiopharmaceuticals

            13.2.2. Therapeutic Nuclear Medicine

                13.2.2.1. Alpha Emitters

                13.2.2.2. Beta Emitters

                13.2.2.3. Brachytherapy Isotopes

        13.3. Market Value Forecast, by Application, 2017-2031

            13.3.1. Cardiology

            13.3.2. Neurology

            13.3.3. Oncology

            13.3.4. Pulmonology

            13.3.5. Gastroenterology

            13.3.6. Others

        13.4. Market Value Forecast, by End-user, 2017-2031

            13.4.1. Hospitals

            13.4.2. Diagnostic Centers

            13.4.3. Research Institutes

        13.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Type

            13.6.2. By Application

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Nuclear Medicine Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Type, 2017-2031

            14.2.1. Diagnostic Nuclear Medicine

                14.2.1.1. PECT Radiopharmaceuticals

                14.2.1.2. PET Radiopharmaceuticals

            14.2.2. Therapeutic Nuclear Medicine

                14.2.2.1. Alpha Emitters

                14.2.2.2. Beta Emitters

                14.2.2.3. Brachytherapy Isotopes

        14.3. Market Value Forecast, by Application, 2017-2031

            14.3.1. Cardiology

            14.3.2. Neurology

            14.3.3. Oncology

            14.3.4. Pulmonology

            14.3.5. Gastroenterology

            14.3.6. Others

        14.4. Market Value Forecast, by End-user, 2017-2031

            14.4.1. Hospitals

            14.4.2. Diagnostic Centers

                14.4.2.1. Individual Practice

                14.4.2.2. Group Practice

            14.4.3. Research Institutes

        14.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Type

            14.6.2. By Application

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2022

        15.3. Company Profiles

            15.3.1. GE Healthcare

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Type Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. Siemens Healthineers

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Type Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. Philips Healthcare

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Type Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. Cardinal Health

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Type Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. Bracco Imaging S.p.A.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Type Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Curium Pharma

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Type Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. Eckert & Ziegler

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Type Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Jubilant Radiopharma

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Type Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Lantheus Medical Imaging

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Type Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

                15.3.9.5. Strategic Overview

            15.3.10. Nordion, Inc.

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Type Portfolio

                15.3.10.3. Financial Overview

                15.3.10.4. SWOT Analysis

                15.3.10.5. Strategic Overview

            15.3.11. Advanced Accelerator Applications (AAA)

                15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.2. Type Portfolio

                15.3.11.3. Financial Overview

                15.3.11.4. SWOT Analysis

                15.3.11.5. Strategic Overview

            15.3.12. IBA Radiopharma Solutions

                15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.12.2. Type Portfolio

                15.3.12.3. Financial Overview

                15.3.12.4. SWOT Analysis

                15.3.12.5. Strategic Overview

            15.3.13. NorthStar Medical Radioisotopes

                15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.13.2. Type Portfolio

                15.3.13.3. Financial Overview

                15.3.13.4. SWOT Analysis

                15.3.13.5. Strategic Overview

            15.3.14. Polatom

                15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.14.2. Type Portfolio

                15.3.14.3. Financial Overview

                15.3.14.4. SWOT Analysis

                15.3.14.5. Strategic Overview

            15.3.15. Isotopia Molecular Imaging

                15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.15.2. Type Portfolio

                15.3.15.3. Financial Overview

                15.3.15.4. SWOT Analysis

                15.3.15.5. Strategic Overview

    List of Table

    Table 01: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 02: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031

    Table 03: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 04: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 05: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 06: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 07: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031

    Table 08: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 09: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 10: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 11: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031

    Table 12: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 13: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 14: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 15: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031

    Table 16: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 17: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 18: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 19: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031

    Table 20: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 21: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 23: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031

    Table 24: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    List of Figure

    Figure 01: Global Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02: Global Nuclear Medicine Market Value Share, by Type, 2022

    Figure 03: Global Nuclear Medicine Market Value Share, by Application, 2022

    Figure 04: Global Nuclear Medicine Market Value Share, by End-user, 2022

    Figure 05: Global Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 06: Global Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 07: Global Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031

    Figure 08: Global Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031

    Figure 09: Global Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 10: Global Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031

    Figure 13: Global Nuclear Medicine Market Value Share Analysis, by Region, 2022 and 2031

    Figure 14: Global Nuclear Medicine Market Attractiveness Analysis, by Region, 2023-2031

    Figure 15: North America Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031

    Figure 16: North America Nuclear Medicine Market Value Share Analysis, by Country, 2022 and 2031

    Figure 17: North America Nuclear Medicine Market Attractiveness Analysis, by Country, 2023-2031

    Figure 18: North America Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 19: North America Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 20: North America Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031

    Figure 21: North America Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031

    Figure 22: North America Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 23: North America Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031

    Figure 24: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031

    Figure 25: Europe Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 26: Europe Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 27: Europe Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 28: Europe Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 29: Europe Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031

    Figure 30: Europe Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031

    Figure 29: Europe Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 30: Europe Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031

    Figure 31: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031

    Figure 32: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 33: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 34: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 35: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 36: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031

    Figure 37: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031

    Figure 38: Asia Pacific Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 39: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031

    Figure 40: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031

    Figure 41: Latin America Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 42: Latin America Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 43: Latin America Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 44: Latin America Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 45: Latin America Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031

    Figure 46: Latin America Nuclear Medicine Market Attractiveness Analysis, by Application, 2023-2031

    Figure 47: Latin America Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 48: Latin America Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031

    Figure 49: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031

    Figure 50: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 51: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 52: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 53: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 54: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031

    Figure 55: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031

    Figure 56: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 57: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 58: Global Nuclear Medicine Market Share Analysis By Company (2022)

Copyright © Transparency Market Research, Inc. All Rights reserved